Medicinal Cannabis Access in the ACT: A Regulatory Overview

Medicinal cannabis access in the ACT sits inside a federal system

Roughly 925,000 Australians held an active medicinal cannabis approval as of mid-2024, according to TGA published data. The ACT accounts for a small slice of that, but the territory's dual status, a self-governing territory operating inside the Commonwealth's Poisons Standard, creates a regulatory picture that trips up patients and practitioners alike. Medicinal cannabis access here is easier to understand once the layers are pulled apart.

The short version is this: medicinal cannabis in Australia is a federal matter first, a territory matter second. The Therapeutic Goods Administration sets the scheduling rules that apply everywhere, including every suburb of Canberra. Territory law then sits on top, adding its own possession and supply framework. Neither layer can be ignored, and they do not always point in the same direction.

If the TGA itself is unfamiliar, our explainer on the Therapeutic Goods Administration covers what the regulator does and does not control. Reading the two together makes the territory rules far easier to place.

Federal scheduling: the foundation

Under the Poisons Standard (the document formally titled the Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP), cannabis-derived medicines fall across two schedules depending on their composition. For background on how that document is built and amended, see the Poisons Standard explained.

Products containing cannabidiol (CBD) at certain concentrations, with very low residual tetrahydrocannabinol (THC), can qualify as Schedule 4 (Prescription Only) medicines. Products containing THC above the threshold, which covers the bulk of medicinal cannabis products currently prescribed in Australia, are listed as Schedule 8 (Controlled Drug). That distinction matters enormously for how prescribers access and document these medicines.

Put plainly, the schedule a product sits in determines who may prescribe it, how the prescription must be written, and how the pharmacy must store and record it. A Schedule 4 item is handled like many ordinary prescription medicines. A Schedule 8 item carries tighter controls at each step, which is why the same plant can produce products with very different paperwork attached.

A small number of CBD products have been entered on the Australian Register of Therapeutic Goods, see our ARTG glossary entry for what registration actually means; but the overwhelming majority of medicinal cannabis products in circulation are accessed through unapproved pathways. The distinction between registered and unregistered goods is unpacked further in the ARTG registered versus unregistered medicines article. An unapproved product has not been assessed by the TGA for quality, safety and efficacy in the way a registered medicine has, and that is the reason a separate access pathway exists at all.

The two main access pathways

Most patients reach medicinal cannabis via one of two TGA mechanisms: the Special Access Scheme (SAS) or the Authorised Prescriber pathway. These are distinct.

The SAS-B pathway (the most commonly used category) allows any registered medical practitioner to apply to the TGA on behalf of an individual patient for an unapproved therapeutic good. Each application is patient-specific. Approvals can come through relatively quickly, often within days for SAS-B notifications, though the clinical and documentation requirements sit firmly with the prescribing doctor. The other categories work differently again; see Special Access Scheme Category A and Special Access Scheme Category C for how they compare.

The Authorised Prescriber pathway works differently. A medical practitioner applies to the TGA (usually with endorsement from a Human Research Ethics Committee or specialist college) to become authorised to prescribe a specific unapproved good to a class of patients. Once authorised, they can prescribe to multiple patients without a per-patient SAS application. This is the pathway that tends to attract clinics that see significant volume. Our piece on the Authorised Prescriber Scheme goes through the mechanics.

The most common mistake is mixing the two up, and I'd argue the naming is to blame; it is genuinely counterintuitive. "Special Access Scheme" sounds more special than it is. In practice it is the more common route, while the Authorised Prescriber pathway is the one built around a class of patients rather than an individual.

ACT-specific legislation

The Medicines, Poisons and Therapeutic Goods Act 2008 (ACT) and its accompanying Regulation govern how Schedule 8 controlled medicines, including THC-containing cannabis products, are handled within the territory. The ACT Health Medicines and Poisons team administers these rules locally.

Key points for ACT-based prescribers:

• A Schedule 8 prescribing authorisation from ACT Health is required to prescribe Schedule 8 medicines, including THC-containing medicinal cannabis, in the territory. This is separate from TGA SAS or Authorised Prescriber approval, both federal and territory authorisations are needed.
• Schedule 8 prescriptions in the ACT must meet specific requirements around form, duration, and quantity. The ACT's rules include limitations on the quantity that can be prescribed at one time, and prescriptions must be written on compliant prescription forms.
• Pharmacies dispensing Schedule 8 cannabis products must hold the relevant licences under ACT legislation and maintain the required records.

The reason for two sets of authorisations is structural. The Commonwealth decides whether an unapproved product may be supplied at all, while the territory decides who within its borders may prescribe and dispense a controlled drug. One does not substitute for the other, and a federal approval says nothing about whether a particular doctor holds the territory authorisation.

One thing that catches people out: the ACT's personal cannabis use laws, which decriminalised possession of small amounts for personal use for adults, apply to illicit cannabis under criminal law. They have no bearing on the medicinal cannabis regulatory framework. A patient holding a TGA-approved medicinal cannabis product is operating under an entirely different legal instrument to someone relying on the territory's decriminalisation provisions. These are not the same thing and should not be conflated.

Prescribed products also interact with other territory rules. Our article on driving laws and prescribed cannabis in the ACT covers one of the areas where the distinction between medicinal and illicit use becomes practical.

What products look like on the shelf

Medicinal cannabis products available through Australian pharmacies span a range of formulations: oils, capsules, dried flower for vaporisation, and others. The cannabinoid composition varies considerably. Some are predominantly CBD-dominant; others are THC-dominant or carry a balanced ratio. Some products are described as full-spectrum, meaning they retain a broader range of the plant's constituents including minor cannabinoids and terpenes; others are broad-spectrum or isolate formulations.

Reading a product label is therefore a skill in itself. The ratio of CBD to THC, the formulation type and the form of delivery all differ between products, and those differences are what determine the schedule and the prescribing requirements discussed above.

All products sold through lawful channels in Australia must be manufactured under Good Manufacturing Practice (GMP) standards, whether that manufacturing occurs domestically or overseas. This is a non-negotiable requirement and one the TGA has been increasingly active in enforcing. The GMP requirement is part of why products in this space can be expensive: legitimate manufacturing, testing, and importation under a valid licence cost money.

In my view, the GMP requirement is one of the genuinely good structural features of the Australian framework, even if it creates a cost barrier. The alternative, a loosely regulated market with inconsistent product quality, would be worse for patients and for the broader credibility of the field.

How the endocannabinoid system fits the regulatory picture

Understanding why scheduling distinctions between CBD and THC exist partly comes down to receptor pharmacology. CB1 receptors, which are expressed densely in the central nervous system, are the primary target mediating THC's psychoactive effects, hence the Schedule 8 classification for THC-dominant products and the stricter controls that come with it. CB2 receptors are distributed more peripherally. CBD does not bind with the same affinity to these receptors in the way THC does, which informed the different scheduling threshold. For a broader grounding in how these receptors sit within the endocannabinoid system, that glossary entry is a reasonable starting point.

This is also why the regulatory framework distinguishes so sharply on THC concentration; regulators are essentially tracking psychoactivity risk through the scheduling schedule, not always the full pharmacological picture. Scheduling is a risk-management tool, not a statement about what any product does for any individual, and it should not be read as one.

Scheduling decisions are also revisited over time. For the broader history of how Australian drug scheduling has shifted, see a timeline of Australian drug scheduling.

Practical notes for ACT residents

A few things worth knowing if you are based in or around Canberra and trying to understand this space:

• Any prescription for a Schedule 8 medicinal cannabis product requires both TGA pathway approval (SAS or Authorised Prescriber) and ACT Health S8 prescribing authorisation for your doctor. If a practitioner tells you the process is simpler than this, it is worth asking which authorisations they hold.
• Not all general practitioners in the ACT hold Schedule 8 prescribing authorisations. Specialist clinics focusing on medicinal cannabis are more likely to have these in place, though the GP landscape is changing.
• Dispensing must occur through a licensed pharmacy. Products cannot be lawfully obtained through any other channel, regardless of what is available online or from interstate grey-market sources.
• Laws in this area have changed significantly since 2016 and continue to evolve. Checking directly with ACT Health and the TGA website for current requirements is advisable, this article reflects the framework as at mid-2025, but regulatory detail shifts.

The ACT's jurisdictional patchwork is layered: two systems, federal and territory, occupying the same space and not always perfectly aligned. The point is to check both layers before assuming a single approval covers everything.

Neighbouring jurisdictions run their own territory or state layers on the same federal base, and comparing them can clarify what is ACT-specific. Our overview of medicinal cannabis access in NSW is a useful companion, and the medicinal cannabis access FAQ answers common questions that apply nationally. For official detail, the TGA website and Department of Health and Aged Care remain the reference points.

Sources

• Medicinal Cannabis Hub, Therapeutic Goods Administration (TGA)
• Medicines, Poisons and Therapeutic Goods Act 2008 (ACT), ACT Legislation Register
• Medicinal Cannabis; Australian Government Department of Health and Aged Care
• Poisons Standard (SUSMP), Therapeutic Goods Administration (TGA)

Marcus Hale, Regulatory researcher, TGA & access law